A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

NCT03352765 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: rituximab
DRUG: bendamustine
DRUG: melphalan
PROCEDURE: Autologous Stem Cell Transplantation (ASCT)

Sponsor

Memorial Sloan Kettering Cancer Center